Sales of Novo Nordisk’s weight-loss injection Wegovy were lower than Wall Street analysts had expected in the second quarter, sending shares of the drugmaker down sharply on Wednesday. Novo said Wegovy sales were 11.7 billion Danish krone ($1.7 billion); the FactSet consensus estimate was 13.5 billion DKK ($2 billion).